Related Experiment Video
Updated: Jun 10, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[EGFR Mutations Detection in Non-small Cell Lung Cancer Tissues by Real-time PCR and DNA Sequencing.]
Yongwen Li1, Hongyu Liu, Ying Li
1Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
Background:
Small molecule tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib that target the kinase domain of epidermal growth factor receptor (EGFR) are making successful progression for advanced non-small cell lung cancer patients treatment. The growing evidences revealed that EGFR exon 19 and 21 mutation status in NSCLC patients was correlated with the outcome for EGFR-TKI treatment. In this study, two methods of Real-time PCR and DNA sequencing were compared to detected EGFR exon 19 and 21 mutations.
Methods:
EGFR exon19 mutation del-E746-A750 and exon 21mutation L858R were detected by Real-time PCR and DNA sequencing in 103 NSCLC patients. Chi-square test was used to analyze the consistance.
Results:
There was no significant difference between the two methods. However, Real-time PCR was more convenient and sensitive compared to DNA sequencing.
Conclusions:
Real-time PCR was more suitable for clinical testing than DNA sequencing.
Insights
Real-time PCR and DNA sequencing accurately detect EGFR mutations in non-small cell lung cancer. Real-time PCR offers greater convenience and sensitivity for clinical applications.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for advanced non-small cell lung cancer (NSCLC).
- EGFR exon 19 and 21 mutation status predicts treatment response to EGFR-TKIs.
- Accurate detection of these mutations is crucial for personalized NSCLC therapy.
Purpose:
- To compare the diagnostic performance of Real-time PCR and DNA sequencing for detecting EGFR exon 19 and 21 mutations in NSCLC patients.
- To evaluate the clinical utility of each method for routine testing.
Summary:
- This study evaluated Real-time PCR and DNA sequencing for detecting EGFR exon 19 (del-E746-A750) and exon 21 (L858R) mutations in 103 NSCLC patients.
- Both methods demonstrated comparable accuracy in mutation detection.
- Real-time PCR exhibited superior convenience and sensitivity compared to DNA sequencing.
Impact:
- Real-time PCR is identified as a more suitable method for clinical molecular diagnostics in NSCLC compared to DNA sequencing.
- This finding can guide the selection of efficient and sensitive diagnostic tools for EGFR mutation testing, optimizing patient treatment strategies.
- Enhanced diagnostic efficiency can lead to timely initiation of targeted therapies, potentially improving patient outcomes in NSCLC.
